Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: A case report


Camci C., Sevinc A., ASLAN Y., Kalender M. E., Buyukberber S.

Cancer Chemotherapy and Pharmacology, cilt.63, sa.4, ss.745-748, 2009 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 63 Sayı: 4
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1007/s00280-008-0775-x
  • Dergi Adı: Cancer Chemotherapy and Pharmacology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.745-748
  • Anahtar Kelimeler: Ovarian cancer, Complete remission, Tegafur with uracil
  • Sağlık Bilimleri Üniversitesi Adresli: Hayır

Özet

Background: Ovarian cancer remains one of the most lethal of all gynecologic malignancies, accounting for more deaths than cervical and uterine cancer combined. Advanced ovarian cancer is a chemosensitive tumor and most patients initially respond to platinum-based combination chemotherapy with response rates of about 70%, including a high proportion of complete responses. However, despite aggressive surgery and chemotherapy, more than 80% of patients will relapse and will then be treated with second line chemotherapy with objective responses in about 20% of patients and even lower percentages of complete responses. Case: We observed a 42-months of complete response with administration of 1-[2-tetrahydrofuryl]-5-fluorouracil mixed with uracil (UFT) in patient with platinium refractory ovarian cancer. Conclusion: We report a complete remission of platinium refractory epitelial ovarian cancer with UFT monotherapy that was not reported previously. © 2008 Springer-Verlag.